Cristal Therapeutics and Curapath strengthen collaboration around CliCr® bioconjugation platform

LS@W alumnus Cristal Therapeutics has announced a co-exclusive licensing agreement with Curapath for the CliCr® bioconjugation platform, marking an important next step in the development of advanced drug delivery technologies.

CliCr® is a scalable, site-specific and stable bioconjugation technology designed to efficiently link biomolecules to nanoparticles. Through this agreement, Curapath will act as exclusive CDMO for applying CliCr® in nucleic acid delivery via polymeric and lipid nanoparticles (LNPs), including applications beyond the liver.

The collaboration combines Cristal Therapeutics’ proprietary conjugation chemistry with Curapath’s expertise in next-generation drug delivery systems. Together, the partners aim to accelerate the development of targeted and safer therapeutic solutions and expand the use of CliCr® into new application areas.

This milestone reflects the continued progress of Cristal Therapeutics in translating enabling technologies into clinically and industrially relevant solutions, while strengthening Europe’s drug delivery ecosystem.

For more details, see the full press release from Cristal Therapeutics and Curapath.